1. Home
  2. APAM vs ADPT Comparison

APAM vs ADPT Comparison

Compare APAM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$36.18

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$21.50

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
ADPT
Founded
1994
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.7B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
APAM
ADPT
Price
$36.18
$21.50
Analyst Decision
Hold
Strong Buy
Analyst Count
5
9
Target Price
$43.00
$17.78
AVG Volume (30 Days)
853.5K
4.0M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
10.81%
N/A
EPS Growth
10.66
63.89
EPS
0.76
N/A
Revenue
$1,196,688,000.00
$276,976,000.00
Revenue This Year
$5.96
$3.98
Revenue Next Year
$5.05
$22.72
P/E Ratio
$46.59
N/A
Revenue Growth
7.63
54.77
52 Week Low
$33.96
$9.96
52 Week High
$48.46
$22.80

Technical Indicators

Market Signals
Indicator
APAM
ADPT
Relative Strength Index (RSI) 53.98 67.51
Support Level $35.20 $15.08
Resistance Level $38.07 N/A
Average True Range (ATR) 0.95 1.16
MACD 0.07 0.26
Stochastic Oscillator 78.94 79.42

Price Performance

Historical Comparison
APAM
ADPT

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: